爱尔康公司近日指出,针对LENSAR Inc收购案的延长监管审核已持续近一年。审批流程的长期延误及相关衍生成本,显著降低了此项交易的经济效益与战略价值。公司最终认定,在当前条件下继续推进交易已不具备商业合理性。
爱尔康公司近日指出,针对LENSAR Inc收购案的延长监管审核已持续近一年。审批流程的长期延误及相关衍生成本,显著降低了此项交易的经济效益与战略价值。公司最终认定,在当前条件下继续推进交易已不具备商业合理性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.